Medical Affairs Reputations (US) [RA]

September 2017 | | ID: MC4ECCA7D99EN
FirstWord

Abstracts

How well does your Rheumatoid Arthritis medical affairs team performance compare with the rest?

How well does your Rheumatoid Arthritis medical affairs team performance compare with the rest?

Use Medical Affairs Reputations: Rheumatoid Arthritis 2017 (US) to discover how your team can better meet the high expectations of physicians at the frontline.

This report compares the current activities of medical affairs teams for the 11 leading treatments for rheumatoid arthritis from AbbVie, Amgen, BMS, Janssen Biotech, Pfizer, Regeneron, Roche, Sanofi and UCB. It shows:

• How physicians rate each team overall, and for 12 key medical affairs services.
• What is most important to physicians, plus what can be done better.
• How, and how often physicians want to meet with your team.

It’s time to find out exactly how well your medical affairs team is performing against fierce competition – and establish an action plan to gain competitive advantage.

Interested in the European market? Click here to see the EU5 Edition.

Request sample pages

Top Takeaways

• Are leaders losing their focus? One team strides ahead with 77% of physicians recalling an interaction within the last 6 months, but this is down from 85% in 2016. Does this suggest a lack of focus, and how does your team stack up?
• Are patients the main focus, or is it something else? How much do US physicians rely on medical affairs to help them improve patient access, education and outcomes? And are they spending more or less time doing this than before?
• It’s not just about biologics. With small molecules becoming a critical component of RA treatment, how does the medical affairs team for one of the key small molecule therapies perform? Are they leaders, or are they laggards?
• Good news for all. Physicians praised every RA brand for at least 4 areas of support provided by medical affairs teams. Where in this mix does your brand sit?
• Information or attitude? When it comes to what physicians recommend in terms of key areas for improvement, is it information, attitude or something else? Could addressing these tip the balance?

Insight into Medical affairs teams for these Rheumatoid Arthritis treatments

• Actemra (tocilizumab; Roche)
• Cimzia (certolizumab pegol; UCB)
• Enbrel (etanercept; Amgen)
• Humira (adalimumab; AbbVie)
• Inflectra (infliximab; Pfizer)
• Kevzara (sarilumab; Sanofi/Regeneron)
• Orencia (abatacept; Bristol-Myers Squibb)
• Remicade (infliximab; Janssen Biotech)
• Rituxan (rituximab; Roche/Biogen)
• Simponi (golimumab; Janssen Biotech)
• Xeljanz (tofacitinib; Pfizer)

A Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of medical affairs teams for 12 leading rheumatoid arthritis brands—answering important questions like:

What do physicians need?

• How, and how often are they using your medical affairs team?
• What services do they consider most important?
• How often should you contact them? What channels are best?

Does your medical affairs team deliver?

• How memorable are your team’s interactions with doctors?
• How do doctors rank your team for performance and satisfaction in 12 key areas?
• How does your team compare to the competition—in each area, and overall?

What needs improvement?

• Are you delivering the services that are most important to doctors?
• Where do you need to improve?
• How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 100 US-based rheumatologists, chosen from the largest community of validated physicians in the world.

All respondents:

• Have been practicing for between 3 and 35 years
• See at least 5 patients a typical month
• Devote at least 50% of their time to direct patient care
• Have interacted with at least one listed product’s medical affairs team in the past 6 months.

We conducted the survey between October 5-28, 2017.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Contents

1. OBJECTIVES, SURVEY METHODOLOGY AND SAMPLING, PRODUCTS INCLUDED IN THE SURVEY, EXECUTIVE SUMMARY

2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS

2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product

3 COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES

3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product

4 PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT

4.1 Preferred interaction media and frequency, and suggestions for improvement

5 APPENDIX